Shu Qin Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shu Qin Wei has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- François Audibert
University of Montreal
5 shared publications William D. Fraser
4 shared publicationsZhong-Cheng Luo
Centre hospitalier universitaire Sainte-Justine Research Center,Montreal,QC H3T 1C5,Canada
4 shared publicationsAnne Monique Nuyt
Centre Hospitalier Universitaire Saint-Justine Research Center, University of Montréal, Montréal, Quebec, Canada
3 shared publications- Isabelle Boucoiran
School of Public Health Université de Montréal Montreal Québec Canada
3 shared publications Sarah Thissier-Levy
Department of Obstetrics and Gynecology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
3 shared publications
Latest Publications
- Open Access
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 172 (7) , 635-645
Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality
Low maternal vitamin D level status is common during pregnancy and is a public health issue worldwide.1-3 Vitamin D, a fat-soluble nutrient and prohormone,2 has classic functions of calcium absorption, metabolism, and bone health and nonclassic actions that may affect various other aspects of health.4 Low vitamin D level status during pregnancy may expose the offspring to a suboptimal nutritional environment during critical phases of fetal development and may have long-term effects on offspring health outcomes.3,5,6 Sufficient vitamin D concentrations are needed during pregnancy to address the increased demand of fetal growth and development because the mother provides all of the vitamin D for the fetus.7
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 172 (7) , 635-645
Open AccessAssociation Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality
Low maternal vitamin D level status is common during pregnancy and is a public health issue worldwide.1-3 Vitamin D, a fat-soluble nutrient and prohormone,2 has classic functions of calcium absorption, metabolism, and bone health and nonclassic actions that may affect various other aspects of health.4 Low vitamin D level status during pregnancy may expose the offspring to a suboptimal nutritional environment during critical phases of fetal development and may have long-term effects on offspring health outcomes.3,5,6 Sufficient vitamin D concentrations are needed during pregnancy to address the increased demand of fetal growth and development because the mother provides all of the vitamin D for the fetus.7
- 11 January 2018
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 119 (3) , 310-319
Prenatal vitamin D status and offspring’s growth, adiposity and metabolic health: a systematic review and meta-analysis
In this systematic review and meta-analysis of observational studies, we aimed to estimate the associations between prenatal vitamin D status and offspring growth, adiposity and metabolic health. We searched the literature in human studies on prenatal vitamin D status and offspring growth in PubMed, up to July 2017. Studies were selected according to their methodological quality and outcomes of interest (anthropometry, fat mass and diabetes in offspring). The inverse variance method was used to calculate the pooled mean difference (MD) with 95 % CI for continuous outcomes, and the Mantel–Haenszel method was used to calculate the pooled OR with 95 % CI for dichotomous outcomes. In all, thirty observational studies involving 35 032 mother–offspring pairs were included. Vitamin D status was evaluated by circulating 25-hydroxyvitamin D (25(OH)D) level. Low vitamin D status was based on each study’s cut-off for low 25(OH)D levels. Low prenatal vitamin D levels were associated with lower birth weight (g) (MD −100·69; 95 % CI −162·25, −39·13), increased risk of small-for-gestational-age (OR 1·55; 95 % CI 1·16, 2·07) and an elevated weight (g) in infant at the age of 9 months (g) (MD 119·75; 95 % CI 32·97, 206·52). No associations were observed between prenatal vitamin D status and other growth parameters at birth, age 1 year, 4–6 years or 9 years, nor with diabetes type 1. Prenatal vitamin D may play a role in infant adiposity and accelerated postnatal growth. The effects of prenatal vitamin D on long-term metabolic health outcomes in children warrant future studies.
- 11 January 2018
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 119 (3) , 310-319
Prenatal vitamin D status and offspring’s growth, adiposity and metabolic health: a systematic review and meta-analysis
In this systematic review and meta-analysis of observational studies, we aimed to estimate the associations between prenatal vitamin D status and offspring growth, adiposity and metabolic health. We searched the literature in human studies on prenatal vitamin D status and offspring growth in PubMed, up to July 2017. Studies were selected according to their methodological quality and outcomes of interest (anthropometry, fat mass and diabetes in offspring). The inverse variance method was used to calculate the pooled mean difference (MD) with 95 % CI for continuous outcomes, and the Mantel–Haenszel method was used to calculate the pooled OR with 95 % CI for dichotomous outcomes. In all, thirty observational studies involving 35 032 mother–offspring pairs were included. Vitamin D status was evaluated by circulating 25-hydroxyvitamin D (25(OH)D) level. Low vitamin D status was based on each study’s cut-off for low 25(OH)D levels. Low prenatal vitamin D levels were associated with lower birth weight (g) (MD −100·69; 95 % CI −162·25, −39·13), increased risk of small-for-gestational-age (OR 1·55; 95 % CI 1·16, 2·07) and an elevated weight (g) in infant at the age of 9 months (g) (MD 119·75; 95 % CI 32·97, 206·52). No associations were observed between prenatal vitamin D status and other growth parameters at birth, age 1 year, 4–6 years or 9 years, nor with diabetes type 1. Prenatal vitamin D may play a role in infant adiposity and accelerated postnatal growth. The effects of prenatal vitamin D on long-term metabolic health outcomes in children warrant future studies.
- 1 May 2013
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 208 (5) , 390.e1-390.e6
Maternal plasma 25-hydroxyvitamin D levels, angiogenic factors, and preeclampsia
- 1 May 2013
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 208 (5) , 390.e1-390.e6
Maternal plasma 25-hydroxyvitamin D levels, angiogenic factors, and preeclampsia
- Top Cited Papers
- 5 February 2013
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 26 (9) , 889-899
Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis
Objective: To estimate the associations between maternal vitamin D status and adverse pregnancy outcomes. Study design: We searched electronic databases of the human literature in PubMed, EMBASE and the Cochrane Library up to October, 2012 using the following keywords: “vitamin D” and “status” or “deficiency” or “insufficiency” and “pregnancy”. A systematic review and meta-analysis were conducted on observational studies that reported the association between maternal blood vitamin D levels and adverse pregnancy outcomes including preeclampsia, gestational diabetes mellitus (GDM), preterm birth or small-for-gestational age (SGA). Results: Twenty-four studies met the inclusion criteria. Women with circulating 25-hydroxyvitamin D [25(OH)D] level less than 50 nmol/l in pregnancy experienced an increased risk of preeclampsia [odds ratio (OR) 2.09 (95% confidence intervals 1.50–2.90)], GDM [OR 1.38 (1.12–1.70)], preterm birth [OR 1.58 (1.08–2.31)] and SGA [OR 1.52 (1.08–2.15)]. Conclusion: Low maternal vitamin D levels in pregnancy may be associated with an increased risk of preeclampsia, GDM, preterm birth and SGA.
- 5 February 2013
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 26 (9) , 889-899
Top Cited PapersMaternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis
Objective: To estimate the associations between maternal vitamin D status and adverse pregnancy outcomes. Study design: We searched electronic databases of the human literature in PubMed, EMBASE and the Cochrane Library up to October, 2012 using the following keywords: “vitamin D” and “status” or “deficiency” or “insufficiency” and “pregnancy”. A systematic review and meta-analysis were conducted on observational studies that reported the association between maternal blood vitamin D levels and adverse pregnancy outcomes including preeclampsia, gestational diabetes mellitus (GDM), preterm birth or small-for-gestational age (SGA). Results: Twenty-four studies met the inclusion criteria. Women with circulating 25-hydroxyvitamin D [25(OH)D] level less than 50 nmol/l in pregnancy experienced an increased risk of preeclampsia [odds ratio (OR) 2.09 (95% confidence intervals 1.50–2.90)], GDM [OR 1.38 (1.12–1.70)], preterm birth [OR 1.58 (1.08–2.31)] and SGA [OR 1.52 (1.08–2.15)]. Conclusion: Low maternal vitamin D levels in pregnancy may be associated with an increased risk of preeclampsia, GDM, preterm birth and SGA.
- 17 January 2013
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (10) , 795-804
Endothelial Nitric Oxide Synthase Gene Polymorphisms and Risk of Preeclampsia
Polymorphisms in endothelial nitric oxide synthase (eNOS) gene may affect the risk of preeclampsia. This systematic review aimed to provide an updated review of the literature to better understand the association between the eNOS gene polymorphisms and the risk of preeclampsia. We searched electronic databases of the human literature in PubMed, EMBASE, and the Cochrane Library up to July 2012. A meta-analysis was conducted on the association of eNOS G894T, T786C, and intron 4b/a polymorphisms with preeclampsia using (1) allele contrast, (2) recessive, (3) dominant, and (4) additive models. Thirty-three studies comprising 10,671 participants met the inclusion criteria. There was statistically significant association between the G894T variant and increased risk of preeclampsia (TT versus TG + GG: odds ratio 1.43, 95% confidence interval: 1.13 to 1.82). However, no significant risk of preeclampsia was observed either in the T786C or the intron 4b/a polymorphism. Homozygosity TT in eNOS G894T variant is significantly associated with an increased risk of preeclampsia.
- 17 January 2013
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (10) , 795-804
Endothelial Nitric Oxide Synthase Gene Polymorphisms and Risk of Preeclampsia
Polymorphisms in endothelial nitric oxide synthase (eNOS) gene may affect the risk of preeclampsia. This systematic review aimed to provide an updated review of the literature to better understand the association between the eNOS gene polymorphisms and the risk of preeclampsia. We searched electronic databases of the human literature in PubMed, EMBASE, and the Cochrane Library up to July 2012. A meta-analysis was conducted on the association of eNOS G894T, T786C, and intron 4b/a polymorphisms with preeclampsia using (1) allele contrast, (2) recessive, (3) dominant, and (4) additive models. Thirty-three studies comprising 10,671 participants met the inclusion criteria. There was statistically significant association between the G894T variant and increased risk of preeclampsia (TT versus TG + GG: odds ratio 1.43, 95% confidence interval: 1.13 to 1.82). However, no significant risk of preeclampsia was observed either in the T786C or the intron 4b/a polymorphism. Homozygosity TT in eNOS G894T variant is significantly associated with an increased risk of preeclampsia.
- 3 December 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (07) , 607-612
Risks for Preeclampsia and Small for Gestational Age: Predictive Values of Placental Growth Factor, Soluble fms-like Tyrosine Kinase-1, and Inhibin A in Singleton and Multiple-Gestation Pregnancies
Objective To determine the accuracy of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and inhibin A in singleton and multiple-gestation pregnancies for predicting preeclampsia (PE) and small for gestational age (SGA). Study Design A prospective cohort nested in a randomized controlled trial of antioxidant supplementation for the prevention of PE. Plasma biomarkers were evaluated at 12 to 18 (visit 1) and 24 to 26 (visit 2) weeks' gestation and expressed as adjusted multiples of the median. Results Multiple-gestation pregnancy (74/772) had a significant impact on all biomarkers' levels. PlGF was the best predictor of PE and SGA. At a 10% false-positive rate, PlGF at visit 1 had 21% sensitivity for predicting PE in singleton versus 60% in multiple-gestation pregnancies. PlGF at visit 1 had a 31% sensitivity in singleton and 27% in multiple-gestation pregnancies for SGA prediction. Conclusion PlGF level was a good predictor of subsequent PE as early as 12 to 18 weeks in multiple-gestation pregnancies but was not clinically useful enough to be used as a single marker. This study was conducted at 17 Canadian Research centers; the coordination center was CHU Sainte-Justine. Presented at the 32nd Annual Meeting of the Society for Maternal-Fetal Medicine, Dallas, Texas, February 6 to 11, 2012.
- 3 December 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (07) , 607-612
Risks for Preeclampsia and Small for Gestational Age: Predictive Values of Placental Growth Factor, Soluble fms-like Tyrosine Kinase-1, and Inhibin A in Singleton and Multiple-Gestation Pregnancies
Objective To determine the accuracy of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and inhibin A in singleton and multiple-gestation pregnancies for predicting preeclampsia (PE) and small for gestational age (SGA). Study Design A prospective cohort nested in a randomized controlled trial of antioxidant supplementation for the prevention of PE. Plasma biomarkers were evaluated at 12 to 18 (visit 1) and 24 to 26 (visit 2) weeks' gestation and expressed as adjusted multiples of the median. Results Multiple-gestation pregnancy (74/772) had a significant impact on all biomarkers' levels. PlGF was the best predictor of PE and SGA. At a 10% false-positive rate, PlGF at visit 1 had 21% sensitivity for predicting PE in singleton versus 60% in multiple-gestation pregnancies. PlGF at visit 1 had a 31% sensitivity in singleton and 27% in multiple-gestation pregnancies for SGA prediction. Conclusion PlGF level was a good predictor of subsequent PE as early as 12 to 18 weeks in multiple-gestation pregnancies but was not clinically useful enough to be used as a single marker. This study was conducted at 17 Canadian Research centers; the coordination center was CHU Sainte-Justine. Presented at the 32nd Annual Meeting of the Society for Maternal-Fetal Medicine, Dallas, Texas, February 6 to 11, 2012.
- 31 January 2012
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 206 (1) , S334
755: Endostatin: a new biomarker of preeclampsia ?
- 31 January 2012
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 206 (1) , S334
755: Endostatin: a new biomarker of preeclampsia ?
- 31 January 2012
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 206 (1) , S336-S337
762: Risk for preeclampsia and intrauterine growth restriction: effective value of PlGF, Sflt-1 and Inhibin A in singleton and multiple pregnancies
- 31 January 2012
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 206 (1) , S336-S337
762: Risk for preeclampsia and intrauterine growth restriction: effective value of PlGF, Sflt-1 and Inhibin A in singleton and multiple pregnancies